Respiratory Today—July 10, 2026

This week’s Respiratory Research update highlights regulatory progress, late-stage clinical development, strategic partnerships, financing activity, and evolving access pathways across pulmonary diseases.

In Today’s Newsletter

Dive deeper

🫁 Celea Therapeutics finances deupirfenidone Phase 3 IPF trial [1] [US • 02 Jul 2026]

https://www.businesswire.com/news/home/20260701663109/en/PureTech-Founded-Entity-Celea-Therapeutics-Completes-%24180-Million-Financing-to-Advance-Deupirfenidone-as-a-Potential-New-Standard-of-Care-to-Treat-Idiopathic-Pulmonary-Fibrosis-IPF
Context: Celea Therapeutics (PureTech-founded entity) plans SURPASS-IPF, a global head-to-head Phase 3 trial in IPF.
Key point: The $180 million financing will support deupirfenidone (LYT-100) versus pirfenidone, with FVC change at week 52 as the primary endpoint.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 Arcturus and Thermo Fisher align on ARCT-032 manufacturing [2] [US • 02 Jul 2026]

https://ir.arcturusrx.com/news-releases/news-release-details/arcturus-therapeutics-announces-strategic-collaboration-thermo
Context: ARCT-032 is Arcturus Therapeutics’ investigational mRNA therapy for cystic fibrosis.
Key point: Thermo Fisher Scientific will provide Phase 3 manufacturing, clinical research and commercial-readiness support.
Implication: Signals pipeline investment and modality expansion.

🇨🇦 Vertex advances ALYFTREK access pathway in Canada [3] [Canada • 06 Jul 2026]

https://www.newswire.ca/news-releases/vertex-signs-letter-of-intent-loi-with-the-pan-canadian-pharmaceutical-alliance-for-alyftrek-for-the-treatment-of-cystic-fibrosis-807026282.html
Context: ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor) is approved in Canada for eligible people with cystic fibrosis aged 6 years and older.
Key point: Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance after positive reimbursement recommendations.
Implication: May expand screening, initiation, and follow-up at scale.

🛡️ Invivyd receives PEMGARDA EUA termination notice [4] [US • 06 Jul 2026]

https://investors.invivyd.com/news-releases/news-release-details/invivyd-announces-receipt-twelve-months-advanced-notice
Context: PEMGARDA (pemivibart) is authorized for COVID-19 pre-exposure prophylaxis in certain immunocompromised adults and adolescents.
Key point: FDA sent Invivyd a Notice of Termination for the EUA, effective 29 Jun 2027 after a 12-month transition period.
Implication: Could affect access planning while Invivyd discusses next regulatory steps with FDA.

🤖 Insilico starts Phase III rentosertib IPF trial [5] [China • 07 Jul 2026]

https://insilico.com/news/xmjsn4l091-insilico-initiates-phase-iii-clinical-tr
Context: Rentosertib is Insilico Medicine’s oral TNIK inhibitor, discovered through its Pharma.AI platform.
Key point: The Phase III IPF trial is expected to enroll 320 patients across 47 centers in China over 52 weeks.
Implication: May influence prescriber choice and payer reviews pending full data.

✂️ Prime Medicine resolves Beam arbitration over PM647 [6] [US • 08 Jul 2026]

https://investors.primemedicine.com/news-releases/news-release-details/prime-medicine-announces-positive-resolution-arbitration-beam
Context: PM647 is Prime Medicine’s investigational Prime Editing therapy for Alpha-1 Antitrypsin Deficiency.
Key point: The tribunal found PM647 is within Prime Medicine’s field under the Beam agreement, with no monetary damages owed.
Implication: Signals pipeline investment and modality expansion.

💨 AstraZeneca licenses Sino COPD candidate TQC3721 [7] [Global • 08 Jul 2026]

https://www.fiercebiotech.com/biotech/astrazeneca-pays-sino-200m-challenger-mercks-copd-drug-ohtuvayre
Context: TQC3721 is Sino Biopharmaceutical’s PDE3/4 inhibitor, with a nebulized formulation in Phase 3 in China.
Key point: AstraZeneca is paying $200 million upfront for ex-China rights, with up to $1.9 billion in milestones.
Implication: Signals pipeline investment and modality expansion.

✅ MHRA approves nerandomilast for IPF and PPF [8] [UK • 08 Jul 2026]

https://www.gov.uk/government/news/nerandomilast-jascayd-approved-to-treat-adult-patients-with-idiopathic-pulmonary-fibrosis-and-progressive-pulmonary-fibrosis
Context: Nerandomilast (Jascayd) is approved for adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis.
Key point: MHRA approved the twice-daily oral medicine, with diarrhoea and weight loss listed as common side effects.
Implication: May influence prescriber choice and payer reviews pending full data.

🌏 Sino Biopharmaceutical gains China rights to GSK inhalers [9] [China • 08 Jul 2026]

https://www.reuters.com/legal/litigation/sino-biopharmaceutical-gsk-expand-alliance-with-china-rights-respiratory-drugs-2026-07-08/
Context: Trelegy Ellipta is used for COPD and asthma maintenance treatment; Anoro Ellipta is used for COPD maintenance treatment.
Key point: Sino Biopharmaceutical’s Chia Tai Tianqing unit secured mainland China commercialization rights from GSK.
Implication: Could streamline initiation and adherence via local commercialization and logistics.

Why it matters

IPF competition is intensifying, with deupirfenidone, rentosertib and nerandomilast all moving across late-stage, approval or access milestones.
Respiratory BD remains active, led by AstraZeneca’s TQC3721 deal and Sino Biopharmaceutical’s expanded GSK alliance.
Cystic fibrosis updates span both access, via ALYFTREK in Canada, and novel modality manufacturing, via ARCT-032.
Regulatory transition remains a key theme, especially for PEMGARDA as its EUA moves toward termination in 2027.
Gene-editing pipeline clarity improved for Prime Medicine after the PM647 arbitration decision.

📚 See the full Respiratory archive on our research hub page

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🧰 See our full range of services. Discover how we can help you.

🎯 Catch up on the Top Respiratory news from the past two weeks, curated by the LucidQuest team.

🎬 Watch on YouTube.

FAQ

What is Celea Therapeutics testing in SURPASS-IPF?

Celea plans to test deupirfenidone (LYT-100) against pirfenidone in adults with IPF, with FVC change at week 52 as the primary endpoint. [1]

What does Thermo Fisher provide for Arcturus ARCT-032?

Thermo Fisher will support Phase 3 manufacturing, clinical research and commercial readiness for ARCT-032, an investigational mRNA therapy for cystic fibrosis. [2]

What changed for Vertex ALYFTREK in Canada?

Vertex signed an LOI with pCPA for ALYFTREK, enabling discussions with provinces and territories on public listings. [3]

When is the PEMGARDA EUA set to terminate?

Invivyd said the FDA Notice of Termination makes the PEMGARDA EUA termination effective on 29 Jun 2027, after a transition period. [4]

What makes Insilico’s rentosertib notable?

Rentosertib is an AI-originated TNIK inhibitor for IPF, now in a Phase III trial expected to enroll 320 patients in China. [5]

What did MHRA approve for IPF and PPF?

MHRA approved nerandomilast (Jascayd), an oral twice-daily medicine for adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. [8]

Entities / Keywords

Celea Therapeutics, PureTech Health, deupirfenidone, LYT-100, SURPASS-IPF, pirfenidone, idiopathic pulmonary fibrosis, IPF
Arcturus Therapeutics, Thermo Fisher Scientific, ARCT-032, mRNA therapy, cystic fibrosis, CF
Vertex Pharmaceuticals, ALYFTREK, vanzacaftor, tezacaftor, deutivacaftor, pCPA, Canada
Invivyd, PEMGARDA, pemivibart, COVID-19 pre-exposure prophylaxis, EUA, FDA, HHS
Insilico Medicine, rentosertib, ISM001-055, INS018_055, TNIK inhibitor, Pharma.AI, GENESIS-IPF
Prime Medicine, Beam Therapeutics, PM647, Prime Editing, Alpha-1 Antitrypsin Deficiency, AATD, SERPINA1
AstraZeneca, Sino Biopharmaceutical, Chia Tai Tianqing, TQC3721, PDE3/4 inhibitor, COPD, Ohtuvayre
MHRA, nerandomilast, Jascayd, progressive pulmonary fibrosis, PPF
GSK, Trelegy Ellipta, Anoro Ellipta, mainland China, asthma, COPD